The PFTK1 gene encodes a cdc2-related serine/threonine protein kinase that has been shown to confer cell migratory properties in hepatocellular carcinoma (HCC). However, the prognostic value and biological mechanism by which PFTK1 promotes HCC motility remain largely unknown. Here, we showed from tissue microarray that common upregulations of PFTK1 in primary HCC tumors (n ¼ 133/180) correlated significantly with early age onset (p40 years), advance tumor grading and presence of microvascular invasion (Pp0.05). To understand downstream phosphorylated substrate(s) of PFTK1, phospho-proteins in PFTK1 expressing and knockdown Hep3B cells were profiled by two-dimensional-polyacrylamide gel electrophoresis mass spectrometric analysis. Protein identification of differential spots revealed b-actin (ACTB) and transgelin2 (TAGLN2) as the two most profound phosphorylated changes affected by PFTK1. We verified the presence of TAGLN2 serine phosphorylation and ACTB tyrosine phosphorylation. Moreover, reduced TAGLN2 and ACTB phosphorylations in PFTK1-suppressed Hep3B corresponded to distinct actin depolymerizations and marked inhibition on cell invasion and motility. Given that TAGLN2 is a tumor suppressor whose function has been ascribed in cancer metastasis, we examined if TAGLN2 is an intermediate substrate in the biological path of PFTK1. We showed in PFTK1-suppressed cells that knockdown of TAGLN2 over-rode the inhibitory effect on cell invasion and motility, and a recovery on actin polymerization was evident. Interestingly, we also found that unphosphorylated TAGLN2 in PFTK1-suppressed cells elicited strong actin-binding ability, a mechanism that possibly halts the actin cytoskeleton dynamics. Site-directed mutagenesis of TAGLN2 suggested that PFTK1 regulates the actinbinding affinity of TAGLN2 through the S83 and S163 residues, which if mutated can significantly affect HCC cell motility. Taken together, our data propose a novel, oncogene-tumor suppressor interplay, where oncogenic PFTK1 confers HCC cell motility through inactivating the actin-binding motile suppressing function of TAGLN2 via phosphorylation.
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Introduction
Hepatocellular carcinoma (HCC) is a highly aggressive tumor that is rapidly fatal. It currently ranks the fifth most common cancer worldwide and the third leading cause of cancer-related deaths globally (Stewart and Kleihues, 2003) . The development of HCC, often arising from chronic liver disease, is a multistep process characterized by progressive accumulation of genetic alterations that cause aberrant cell growth, malignant transformation, vascular invasion and ultimately metastasis. Genome-wide analysis has cataloged a number of causal genetic changes that underscore the molecular basis of HCC development and progression (Herath et al., 2006; Katoh et al., 2007) . We reported previously on regional chr.7q21-q22 over-representations in close association with progression of HCC to advance metastatic tumors (Poon et al., 2006) . Recurrent proximal gains of chr.7q are in fact common in human neoplasms (Knuutila et al., 1998) , where it has been implicated in increased metastatic potentials of colorectal cancer (Nakao et al., 2001) , angiogenesis in prostate tumors (Strohmeyer et al., 2004) and inferior survival of patients with sporadic Burkitt's lymphoma (Garcı´a et al., 2003) . We identified PFTK1 as target proto-oncogene within the aberrant genomic amplicon chr. 7q21-q22 of HCC. Our earlier investigations by ectopic expression and gene knockdown experiments confirmed an important role for PFTK1 in the cellular invasiveness and motility of HCC cells (Pang et al., 2007) . Nevertheless, the biological basis that underlies the action of PFTK1 in conferring cell migratory properties in HCC remains unknown.
The human PFTK1 gene encodes hPFTAIRE protein kinase 1, which has a sequence homology to the Cdc2 kinase (53% identity) in the catalytic region. The central domain of hPFTAIRE1 contains all subdomains that are highly conserved in the Cdc2 superfamily, including the serine/threonine kinase signature. The 6 kb transcript of human PFTK1 is highly expressed in the brain, pancreas, kidney, heart, testis and ovary, but minimally detected in other tissues such as the placenta, lung and liver (Yang and Chen, 2001) . As PFTK1 is a novel member of the Cdc2 family, few studies have been performed to characterize its physiological function or biological importance. We defined a role for PFTK1 as a regulatory factor in the control of HCC cell migration (Pang et al., 2007) . Although it has been long recognized that Cdc2 proteins have vital roles in the control of cell cycle transitions in eukaryotic cells (Kirschner, 1992; Pines, 1992; Solomon, 1993) and would be suspected to have minimal influence on cell migrations, in line with our findings, an earlier study also showed that upregulation of Cdc2 could enhance cell migration through activating cyclin B2 and caldesmon in promoting actin contractility (Manes et al., 2003) . The concept of cell cycle regulator being involved in cell migration was also supported by another study indicating that cyclin D1 contributed to cell motility (Neumeister et al., 2003) .
In this study, we attempted to characterize the phosphorylation targets of PFTK1 in promoting HCC cell motility. We also examined if PFTK1 has prognostic value as a tumor biomarker in HCC by tissue microarray analysis (TMA). Coupling two-dimensional-polyacrylamide gel electrophoresis (2D-PAGE) comparative proteomics with mass spectrometry for protein identification, we obtained information on the phosphoproteins in PFTK1-expressing cells. Our subsequent investigations show compelling evidence to suggest that the tumor suppressor gene transgelin2 (TAGLN2) is a downstream functional target of PFTK1. Because metastasis is the major cause of morbidity and mortality in individuals diagnosed with HCC, understanding the biological basis of HCC cell motility holds much importance in providing new insights into the process of tumor cell dissemination and predicting metastasis.
Results

TMA of PFTK1 expression in HCC
To establish prognostic value of PFTK1 in HCC, we examined the protein expression by TMA in a cohort of 180 paired primary HCC tumors and adjacent nontumoral liver. Immunohistochemical staining of PFTK1 protein showed varying degree of staining intensities ranging from low, moderate to high levels. Examples of PFTK1 protein staining are illustrated in Figure 1a . Of the 180 cases studied, 133 HCC tumors (73.9%) showed distinct PFTK1 upregulations compared with the nonmalignant counterparts (Po0.0001; Figure 1b) .
Furthermore, correlative analysis indicated that increased PFTK1 expressions were associated with early age onset of HCC (o40 years; P ¼ 0.021), advance tumor grading to poorly differentiated state (Po0.0001) and the histological presence of microvascular invasion (P ¼ 0.05) ( Table 1) .
2D-PAGE mass spectrometry analysis for PFTK1 phosphorylation substrates To elucidate the underlying biological action of PFTK1, we applied 2D-PAGE proteomic analysis to compare the phospho-proteins in Hep3B cells with or without PFTK1 knockdown. The use of Hep3B was based on the fact that this cell line exhibits overexpression of PFTK1 and is highly invasive (Pang et al., 2007) . Approximately 2000 spots were resolved by 2D gel and more than 95% spots could be matched across the 2D gel images. Comparing the phospho-proteome obtained from PFTK1 knockdown and Mock control, spot intensities were ranked accordingly to their degree of signal differences. Specifically, we selected those spots that showed evident reduction in quantities following the suppression of PFTK1. These spots likely signify downstream substrates of the PFTK1 kinase. According to the signal intensities scored, top five ranked differential spots were excised from the gel and subjected to further protein identification. Mass spectrometric analysis of digested peptides indicated the top ranked spots to be b-actin (ACTB), TAGLN2, heat-shock protein 70, aldehyde dehydrogenase, 14-3-3 gamma (Figure 2 ).
PFTK1 modulates intracellular cytoskeleton
From the 2D-PAGE mass spectrometric analysis, we identified ACTB as the highest ranked target. This finding underscores a potential role for PFTK1 in the cytoskeletal regulation. To confirm a role for PFTK1 on the actin cytoskeletal organization, we carried out western blot and immunofluorescence analyses on ACTB for its involvement in the filamentous actin structure. We also examined two other major components of the intracellular cytoskeleton, which included vimentin (VIM) for intermediate filaments and b-tubulin (TUBB) for the microtubules. Hep3B cells with PFTK1 stably suppressed were utilized in this study and subsequent investigations. Short hairpin (sh) RNAsuppressed sh-PFTK1-c1 and sh-PFTK1-c2 showed marked inhibition on cell invasion and migration compared with sh-Mock control, whereas an effect on cell viability was not apparent (Supplementary Figure 1) .
Western blot analysis on sh-PFTK1-c1 and sh-PFTK1-c2 for ACTB, VIM and TUBB did not suggest changes in the level of ACTB and TUBB, but much reduced VIM total protein was shown (Figure 3a) . We further investigated the effect of PFTK1 on the intracellular organization of these cytoskeletal components. Immunofluorescence staining revealed a concomitant diminution of VIM in sh-PFTK1-c1 and sh-PFTK1-c2 compared with sh-Mock. More intriguingly, although changes in the total ACTB protein were not suggested, marked depolymerization of actin stress fibers was readily observed in PFTK1-suppressed cells (Figure 3b ). Structural changes on TUBB organization were not indicated. In brief, the data showed that PFTK1 promotes HCC cell motility possibly through enhancing actin polymerization and VIM upregulation.
TAGLN2 and actin phosphorylations
We verified the phosphorylation status of two highest scored proteins, namely TAGLN2 and ACTB, by immunoprecipitation.
Reduced phospho-serine TAGLN2 and phospho-tyrosine ACTB in sh-PFTK1-c1 and sh-PFTK1-c2 were found (Figure 4bi , ii). To confirm an effect of PFTK1 on the serine phosphorylation of TAGLN2, we ectopically expressed flag-TAGLN2 in PFTK1-suppressed Hep3B and HKCI-4 cells and found a concordant reduction in serine phosphorylation of TAGLN2 (Figure 4ci , ii). Similar to Hep3B, the HCC cell line HKCI-4 also exhibits upregulation of PFTK1 when compared with normal livers. Conversely, ectopic expression of PFTK1 in immortalized hepatocyte cell line L02 that contains negligible endogenous PFTK1 expression readily showed serine phosphorylation of the TAGLN2 protein ( Figure 4ciii ). Intriguingly, we also found that knockdown of PFTK1 not only affected the phospho-serine status of TAGLN2, but also resulted in marked accumulation of TAGLN2 total protein ( Figure 4a ).
Studies on TAGLN have shown that it is an actin fiber-binding protein (Assinder et al., 2009) . However, serine residues phosphorylation on TAGLN greatly weakens this actin-binding ability (Assinder et al., 2009) . We carried out immunoprecipitation analysis to confirm if TAGLN2 serine phosphorylation has an effect on its actin-binding capability in HCC. Our pull-down assay confirmed that binding of TAGLN2 to actin was evident in both Hep3B and HKCI-4, whereas impaired interaction between the two proteins was readily found in PFTK1-expressing control cells (Figure 4ci , ii). On the other hand, serine phosphorylation on TAGLN2 abolished the binding of TAGLN2 to actin in PFTK1-expressing L02 cells (Figure 4ciii ). Our finding would thus propose that serine phosphorylation on TAGLN2 elicited by PFTK1 kinase has an inhibitory effect in the physical interaction of TAGLN2 to actin in HCC.
TAGLN2 knockdown rescues motile phenotype in PFTK1-supressed cells To determine if TAGLN2 is a functional downstream substrate of PFTK1, we performed knockdown assay of PFTK1 kinase regulates actin-binding affinity of TAGLN2 through S83 and S163 residues To define PFTK1-targeted sites on TAGLN2, we constructed a panel of phospho-defective mutants (S11A, S83A, S94A, S145A, S155A, S163A, S185A) with all serine (S) residues on TAGLN2 replaced with alanine (A), and examined these single mutated constructs for their functional effect on actin binding. In Hep3B sh-Mock cells, immunoprecipitation against flag-labeled wild-type TAGLN2 and phospho-defective constructs showed complexes of TAGLN2 with ACTB in cells transfected with S83A and S163A mutants, but not other constructs, suggesting that these mutants abrogated the inhibitory effect of PFTK1 on the PFTK1 modulates HCC cell motility through TAGLN2 WKC Leung et al physical interaction between TAGLN2 and ACTB ( Figure 7ai ). To corroborate, S83 and S163 residues are essential for actin binding, phospho-mimetic mutants (S83D and S163D) with an aspartic acid (D) substitution of S83 and S163, respectively, were created. We transfected the phospho-mimetic mutants into PFTK-suppressed Hep3B cells, and found that the magnitude of actin binding was impeded in the presence of S83D and S163D mutants when compared to wildtype TAGLN2 (Figure 7bi ). Our data therefore underline much importance for S83 and S163 residues on TAGLN2 in its actin-binding capacity.
PFTK1 regulates HCC cell migratory phenotypes via S83 and S163 of TAGLN2 To assert the functionality of identifying serine residues in regulation of HCC cell motility, we transfected phospho-defective TAGLN2 mutants S83A and S163A into Hep3B sh-Mock cells. In line with their actinbinding capacity as shown in Figure 7ai , a strong retardation in the cell migratory phenotype was found (Po0.05) (Figure 7aii ). The reverse was suggested when phospho-mimetic mutants S83D and S163D were transfected into PFTK1-suppressed Hep3B cells, where an increase in cell migration was suggested (Po0.05) Figure 2 Comparative proteomics analysis for PFTK1-phosphorylated proteins. Enriched phosphoproteins derived from PFTK1-knockdown (PFTK1-kd) Hep3B and Mock experiments were subjected to 2D-PAGE. After separation by pI range and molecular weight, protein spots were matched across the 2D-PAGE images of PFTK1-kd and Mock for spots with evident reduction in quantities following PFTK1 suppression. Differentially expressed spots were analyzed by mass spectrometry for protein identification and later ranked according to fold induced. The top five phosphorylated proteins were highlighted.
PFTK1 modulates HCC cell motility through TAGLN2 WKC Leung et al ( Figure 7bii ). Taken together, our findings support the notion that residues S83 and S163 on TAGLN2 are functional targets of PFTK1 in the control of HCC cell motility.
PFTK1 regulates TAGLN2 and VIM independently As downregulation of VIM was readily found in PFTK1-supressed cells, we next examined if PFTK1 influenced on VIM expression through TAGLN2. (ci, ii, iii) Pull-down assays against exogenous expressed flag-TAGLN2 verified a concordant decline in phospho-serine level of TAGLN2 in PFTK1-suppressed Hep3B and HKCI-4, whereas ectopic expression of green fluorescent protein-tagged PFTK1 in L02 showed an increase in serine phosphorylation. (ci, ii, iii) Co-immunoprecipitation assays showed a diminution in the actin-binding ability of TAGLN2 in PFTK1-expressing cells, whereas in PFTK1-knockdown cells the physical interaction between TAGLN2 and ACTB was evident.
A time-course study of TAGLN2 sequestration at 48, 60 and 72 h post-transfection in sh-PFTK1-c2 cells did not suggest an influence on the VIM protein ( Figure 8a ). Our findings would suggest that PFTK1 regulates the motile phenotype of HCC cell through regulating VIM expression and TAGLN2-actin pathway independently.
Discussion
In this study, we were able to establish a prognostic value for PFTK1 in human HCC, where common PFTK1 overexpressions correlated with advance tumor histology, the presence of micro-vascular invasion and the likely indication of an early age onset. As vascular invasion frequently occurs in HCC and often predicts tumor invasion and metastasis (Poon et al., 1999) , our finding may be interpreted as PFTK1 overexpressions that correlate with a more aggressive tumor phenotype. We also obtained functional evidence showing the mechanistic action of PFTK1 protein kinase through an intermediate substrate TAGLN2. It is therefore plausible that in primary HCC tumors upregulation of oncogenic PFTK1 actively phosphorylates TAGLN2, a process by which it inactivates the suppressive effect of TAGLN2 on actin polymerization, leading to increased cellular invasiveness and motility. Interestingly, we found an accumulation of TAGLN2 total protein consequential to the knockdown of PFTK1. Although this may have been due to a delay in proteosomal degradation or a positive feedback on the endogenous production of TAGLN2 from the serine-unphosphorylated status, the actual fact is that an increase in TAGLN2 level may well have augmented its tumorsuppressive effect on the cell migration through an increased magnitude of actin-binding capacity. In this regard, we postulate that the serine-unphosphorylated status of TAGLN2 is the active tumor-suppressing state with the actin-binding function. We were able to further show the importance of serine residues S83 and S163 on TAGLN2 in its actin-binding capability and their effect on HCC cell migration. PFTK1-expressing cells transfected with abrogating mutants S83A and S163A showed enhanced physical interaction of TAGLN2 to actin and an inhibition on cell motility. A reverse was suggested from phospho-mimetic study where S83D and S163D mutants of TAGLN2 promoted HCC migration, despite the cells being deficient of PFTK1 expression. Our findings strongly support the fact that S83 and S163 residues on TAGLN2 are the essential components in the PFTK1-TAGLN2 cascade. In support to our findings, in vitro co-sedimentation assays have shown that TAGLN2 could bind to actin and/or cause actin gelation through specific binding sites, which if serine phosphorylated could greatly reduce its actin-binding capability (Fu et al., 2000) . Given the importance of actin cytoskeleton on cell migration and tumorigenesis, understanding proteins involved in the binding and regulation of actin organization should provide potential tumor markers and targets for treatment regimens. TAGLN, also named the smooth muscle protein 22-a (SM22-a), is an actin stress fiber-associated protein (Assinder et al., 2009) . It is frequently downregulated in breast, colon (Shields et al., 2002; Wulfkuhle et al., 2002) and prostate cancers (Yang et al., 2007) , where a tumor suppressor function has been proposed. In colorectal cancer, negative TAGLN expression has further been reported to be an independent prognostic indicator for shorter patient's survival (Zhao et al., 2009) , whereas a role in impeding metastasis was suggested in breast carcinoma (Xu et al., 2010) . TAGLN also acts to suppress the expression of metallo-matrix proteinase MMP9, which is an important enzyme involved in the tissue remodeling during cancer cells invasion into the surrounding tissues (Nair et al., 2006) . In this study, we support TAGLN2 as an inhibitor on HCC cell motility through its suppressive effect on actin polymerization. We observed RNA interference targeting of TAGLN2 could counteract the inhibitory effect of sh-PFTK1 on the migratory properties of HCC cells. Nevertheless, although knockdown of TAGLN2 was able to rescue HCC cell invasion and motility with apparent re-emergence of actin stress fiber polymerization, the extent of recovery was only partial when compared with sh-Mock experiment. These findings would invariably suggest that other downstream targets of PFTK1 are likely involved in the control of HCC cell migration. We showed from 2D-PAGE mass spectrometry few phosphorylation targets of PFTK1, including ACTB tyrosine phosphorylation. As PFTK1 is a serine/ threonine protein kinase, it is probable that ACTB tyrosine phosphorylation has resulted from the indirect effects of the PFTK1 cascade, whereas TAGLN serine phosphorylation is likely consequential to a direct kinase activity. Nevertheless, it is worth noting that studies have established a close relation between actin phosphorylation and cytoskeleton remodeling (Rush et al., 2005; Baek et al., 2008) . Specifically, ACTB tyrosine phosphorylation has been shown to induce considerable actin re-organization and cytoskeletal rearrangement (Rush et al., 2005) . In fact, tyrosine phosphorylation of actin can protect its D-loop structure from protease cleavage, resultant in a more stable conformation of the actin D-loop than the unphosphorylated form (Baek et al., 2008) . Conformational stability of the D-loop holds much importance in conferring cell motile properties, which if unstable can result in a weakened contractile force and much reduced gliding velocity (Kubota et al., 2009) . Our finding of reduced ACTB tyrosine phosphorylation in the PFTK1-suppressed cells would seem to be in line with the development of a less stable actin structure, which could have contributed to the repression on HCC cell migration. PFTK1 knockdown could also simultaneously abrogate the expression of VIM, a well-known marker for mesenchymal feature and a structural protein constituting the intermediate filaments of the intracellular cytoskeleton. The process of epithelial-to- PFTK1 regulates HCC cell migration through S83 and S163 of TAGLN2. (ai, ii) Phospho-defective mutants of TAGLN2 expressed in Hep3B sh-Mock were immunoprecipitated by flag antibody and detected by ACTB antibody. Actin binding were suggested in the PFTK1-expressing sh-Mock with phospho-defective constructs S83A and S163A compared with wild-type (WT) TAGLN2 transfection. Impeded cell migratory phenotypes were also suggested in sh-Mock transfected with S83A and S163A (*Po0.05; **Po0.01). (bi, ii) Phospho-mimetic assays illustrated the loss or reduced actin binding of TAGLN2 in PFTK1-suppressed Hep3B transfected with S83D and S163D. In addition, S83D and S163D expression in PFTK1-suppressed cells enhanced cell motility (*Po0.05). PFTK1 modulates HCC cell motility through TAGLN2 WKC Leung et al mesenchymal transition attributes to the trans-differentiation of epithelial cells into fibroblastic, migratory cells with mesenchymal characteristics (Vincent-Salomon and Thiery, 2003) . This mesenchymal phenotype is a hallmark of tumor cells acquiring migratory and aggressive phenotypes. Thus, loss of VIM expression detected from the knockdown of PFTK1 could be suggestive of a regression on mesenchymal features and a reduced cell migratory potential. The precise involvement of PFTK1 in the epithelial-to-mesenchymal transition process however remains to be ascertained. The acquisitions of cell migratory and invasive abilities are pre-requisite for cancer cells to invade and metastasize. This process involves multiple intracellular cytoskeletal components and complex orchestration of biological pathways, often involving intricate interplay between proteins. In this study, our work outlined the merit of 2D-PAGE mass spectrometric proteomics in short-listing downstream phosphorylated substrates of a candidate protein kinase. We showed that suppression of PFTK1 expression can significantly impair HCC cell invasion and migration; meanwhile, siRNA-mediated knockdown of TAGLN2, a phosphorylated target of PFTK1 kinase, can markedly rescue HCC cell migration through actin stress fiber formation. A schematic diagram highlighting the relationship between PFTK1 kinase, TAGLN2 and actin is illustrated in Figure 8b . This newly identified oncogene-tumor suppressor cascade, where oncogenic PFTK1 inactivates a tumor suppressor gene TAGLN2 via phosphorylation, provides a new avenue for better understanding hepatic tumorigenesis, especially on tumor cell dissemination and metastasis, and may facilitate the development of potential therapeutics against HCC.
Materials and methods
Antibodies
Immunohistochemical staining on TMA was performed using primary antibody against the PFTK1 gene (hPFTAIRE1 kinase) (Abnova Incorporation, Taipei City, Taiwan). Other antibodies used included anti-VIM (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-TUBB (Invitrogen, Carlsbad, CA, USA), anti-ACTB (Sigma, St Louis, MO, USA), anti-TAGLN2 (Santa Cruz Biotechnology), anti-phosphotyrosine (Invitrogen), anti-phospho-serine (Chemicon International, Temecula, CA, USA), anti-phospho-threonine (Sigma), anti-GAPDH (Chemicon) and anti-flag (Sigma). For immunofluorescence study, Alexa Fluor 488 anti-immunoglobulin G and Alexa Fluor 594 anti-immunoglobulin G were obtained from Invitrogen.
HCC tissue microarray
Formalin-fixed paraffin-embedded archive tissue of 180 paired HCC tumor and adjacent non-tumoral liver were arranged in tissue array blocks. Three tissue cores were taken from each case, and the paired tumor and adjacent non-tumoral tissues were printed sidewise in the same block. Five-mm sections were stained for PFTK1 protein according to procedure described previously (Wong et al., 2009) . The immunohistochemistry grading of PFTK1 was achieved by scoring the average percentage of positive cells from three cores of each HCC case and non-tumoral liver tissue. The overall grading defined nil to 10% staining as weak, 11-40% as moderate and X41% as high.
2D-PAGE comparative proteomics, image acquisition and data analysis Phospho-proteins from siPFTK1-transfected Hep3B cells and siScramble-transfected Mock control were enriched by PhosphoProtein Purification Kit (Qiagen, Hilden, Germany). In first dimension isoelectric focusing, 12.5 mg enriched phosphoproteins were immobilized on a nonlinear gradient of pH 3-10 (Bio-Rad Laboratories, Hercules, CA, USA). The second dimension was performed in 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis gradient gel (Bio-Rad Laboratories). Gels were later silver stained by Plus-one (GE Healthcare, Piscataway, NJ, USA). All of the samples were run in duplicate to ensure consistency. Gels scanned on calibrated densitometer GS-800 were quantified and analyzed by the PDQuest 2-D Analysis software ver7.11 (Bio-Rad Laboratories). The quantification of individual spots was normalized against the total valid spots of each image. Spots that showed X2-fold downregulation following PFTK1 knockdown were considered differentially expressed, and further processed for protein identification.
Protein identification by mass spectrometry peptide fingerprinting According to gel image analysis, protein spots were excised from the gels. Following trypsin digestion (12.5 ng/ml), peptides were subjected to mass spectrometric analysis (4800 MALDI-TOF/TOF Mass Spectrometer, Applied Biosystems, Foster City, CA, USA). The acquired masses of tryptic peptide digests were submitted to Mascot search engine to obtain the protein identities by peptide mass fingerprinting approach (http://www.matrixscience.com/).
Cell culture
Hep3B was purchased from American Type Culture Collection (ATCC, Rockville, MD, USA), whereas HKCI-4 was established from our laboratory (Pang et al., 2002 ). An immortalized hepatocyte cell line L02 was kindly provided by Prof. Xin-Yuan Guan from the University of Hong Kong. Compared with normal liver controls, both Hep3B and HKCI-4 exhibit upregulation of PFTK1, whereas L02 elicits negligible expression. L02 was transiently transfected with expression construct of green fluorescent protein-tagged PFTK1 as reported previously (Pang et al., 2007) . The protein expression of green fluorescent protein-fused PFTK1 protein was confirmed by western blot. The expression of PFTK1 in Hep3B was stably suppressed by vector-based short hairpin RNA interference according to method described (Pang et al., 2007) . In HKCI-4 cells, PFTK1 expression was transiently suppressed using siRNA obtained from Dharmacon (Chicago, IL, USA). PFTK1 primers used were: 5 0 -CTTGACATGTGG GGAGTAGGTT-3 0 (sense) and 5 0 -CCATGTGTCCTCATTT GGTG-3 0 (antisense). Triplicate reactions were normalized against reference GAPDH. In rescue experiments, siRNA duplexes targeting TAGLN2 (Dharmacon) were transfected into PFTK1-suppressed cells using Lipofectamine 2000 (Invitrogen) . The protein expression of TAGLN2 was monitored by western blot analysis to ensure efficient knockdown.
Flag-labeled TAGLN2 expression vector and mutant constructs Amplified fragments of the human wild-type TAGLN2 (KIAA0120) cDNA was digested with EcoRI and SalI and cloned into pflag-CMV2 to generate a flag-TAGLN2 construct.
Phospho-defective (S11A, S83A, S94A, S145A, S155A, S163A and S185A) and phospho-mimetic (S83D and S163D) TAGLN2 mutants were constructed by the QuikChange sitedirected mutagenesis kit (Stratagene, La Jolla, CA, USA) using the wild-type flag-TAGLN2 as template. Primers employed in cloning are listed in Supplementary Table 1 . The authenticity of all constructs was verified by DNA sequencing.
Cell viability assay Cells were assessed daily for cell viability on at least 7 consecutive days by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide. Measurements made at 570 nm from five replicates in two independent experiments were expressed as a percentage of maximum absorbance.
Cell invasion and motility assays
The cell invasive ability through Matrigel (BD Biosciences, Sparks, MD, USA) and cell motility through Transwell (Corning Incorporated, Cambridge, MA, USA) were assessed as described previously (Pang et al., 2007) . Cells invaded through to the underside of the membrane were scored for at least 10 microscope fields. The mean value of invading and migrating cells was expressed as a percentage relative to mock control. Each experiment was performed in replicate inserts and the mean value expressed from three independent experiments.
Immunoprecipitation and western blotting Protein lysates incubated with specified antibody for 2 h at 4 1C were immunoprecipitated by rec-Protein G-Sepharose (Invitrogen). Resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the immune complexes were analyzed by western blot. The technique of western blot was performed using standard technique as reported before (Pang et al., 2007) .
Immunofluorescence analysis
Cells fixed in 4% paraformaldehyde were permeabilized with 0.5% Triton X-100. Filamentous actins were stained with tetramethylrhodamine B isothiocyanate-labeled phalloidin (Sigma) or antibodies as indicated. Counterstained with 4 0 ,6-diamidino-2-phenylindole, cells were examined by confocal microscopy (LSM5 PASCAL; Carl Zeiss, Gottingen, Germany).
Statistical analysis
The Student t-test was used to assess the immunohistochemical score on PFTK1 protein from TMA, mRNA expression of PFTK1 in stable clones and the functional effects of TAGLN2 knockdown in PFTK1-suppressed Hep3B and HKCI-4 cells. The test was also applied in the functional analyses of phospho-defective and phospho-mimetic mutants on Hep3B cells. Correlative analysis of PFTK1 score with clinicopathological features of HCC tumors was examined by Spearman's r test. A difference was considered significant when Pp0.05. All statistical analysis was performed using SPSS for Windows 10.0 and Graphpad Prism 3.0.
Abbreviations 2D-PAGE, two-dimensional polyacrylamide gel electrophoresis.
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